Patents
Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320)
06/2009
06/18/2009US20090155774 Fluorescence resonance energy transfer screening assay for the identification of HIV-1 envelope glycoprotein-medicated cell
06/18/2009US20090155350 Chlamydia antigens and protein vaccine
06/18/2009US20090155302 Antigen Arrays for Treatment of Allergic Eosinophilic Diseases
06/18/2009US20090155299 Antibodies for the Detection of Bacillus Anthracis and Vaccine Against B. Anthracis Infections
06/18/2009US20090155295 Vaccine
06/18/2009US20090155290 Antigen
06/18/2009US20090155289 Furin-cleavable peptide linkers for drug-ligand conjugates
06/18/2009US20090155286 Type I interferon blocking agents for prevention and treatment of psoriasis
06/18/2009US20090155284 Hgf-sf monoclonal antibody combinations
06/18/2009US20090155283 Noncompetitive Domain Antibody Formats That Bind Interleukin 1 Receptor Type 1
06/18/2009US20090155282 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
06/18/2009US20090155281 Methods of using antibodies that bind both bcma and taci
06/18/2009US20090155280 Immunoglobulin Cleavage Fragments as Disease Indicators and Compositions for Detecting and Binding Such
06/18/2009US20090155279 Pseudomonas Aeruginosa Outer Membrane Protein PA5158
06/18/2009US20090155277 Use of immunesuppressant receptor
06/18/2009US20090155276 NOVEL DKKL-1 Splice Product Modulators for Cancer Diagnosis and Therapy
06/18/2009US20090155275 Multispecific epitope binding proteins and uses thereof
06/18/2009US20090155274 Nerve growth factor specific immunoglobulin for prevention and treatment of chronic pain, nervous system, inflammatory, skin and bone disorders; osteoarthritis
06/18/2009US20090155273 Remedies for inflammatory bowel diseases
06/18/2009US20090155271 pro-inflammatory cytokines, interleukins (IL-17A, IL-17F)
06/18/2009US20090155269 Mesothelin antibody protein fusions and methods of use
06/18/2009US20090155268 Growth Factor Binding Constructs Materials and Methods
06/18/2009US20090155267 Molecule and chimeric molecules thereof
06/18/2009US20090155266 Methods and Compositions Relating to Vascular Endothelial Growth Factor and TH2 Mediated Inflammatory Diseases
06/18/2009US20090155264 Novel composition and methods for the treatment of psoriasis
06/18/2009US20090155263 Compositions and methods for the treatment of immune related diseases
06/18/2009US20090155262 Cytotoxicity mediation of cells evidencing surface expression of CD63
06/18/2009US20090155258 Peptide-based passive immunization therapy for treatment of atherosclerosis
06/18/2009US20090155257 Immunoglobulin variants and uses thereof
06/18/2009US20090155256 Immunotherapy Regimes Dependent On APOE Status
06/18/2009US20090155255 Cd23 binding molecules and methods of use thereof
06/18/2009US20090155254 Affinity Regions
06/18/2009US20090155253 Anti-cd20 antibodies and fusion proteins therof and methods of use
06/18/2009US20090155252 Using vascular endothelial growth factor-D (VEGF-D) specific immunoglobulin for treatment and prevention of cell proliferative and tumor disorders
06/18/2009US20090155251 Polypeptide compounds for inhibiting angiogenesis and tumor growth
06/18/2009US20090155250 Monoclonal antibodies against orthopoxviruses
06/18/2009US20090155249 Humanized antibody igg1
06/18/2009US20090155248 Antibodies to MT-SP1 serine protease
06/18/2009US20090155246 Antibodies Specific For Soluble Amyloid Beta Peptide Protofibrils and Uses Thereof
06/18/2009US20090155242 Polypeptide fusion comprising three nonoverlapping domains for use as tool in identifying modulator for enhancing immune response
06/18/2009US20090155241 Prophylactic/therapeutic agent for cancer
06/18/2009US20090155234 Detection of mutations in a gene associated with resistance to viral infection, mx1
06/18/2009US20090155219 Methods for damaging cells using effector functions of anti-gfra1 antibodies
06/18/2009US20090155213 Lactobacillus acidophilus nucleic acids and uses thereof
06/18/2009US20090155205 HUMAN ANTIBODIES THAT BIND HUMAN TNFa
06/18/2009US20090155204 Methods for treating disorders involving monocytes
06/18/2009US20090155172 Antibodies to MAGMAS and uses thereof
06/18/2009US20090155165 Anti-igf-i receptor antibody
06/18/2009US20090155164 Human c-fms antigen binding proteins
06/18/2009CA2709305A1 Compositions and methods for early pregnancy diagnosis
06/18/2009CA2709151A1 Impaired wound healing compositions and treatments
06/18/2009CA2708790A1 Remedies for pemphigus containing anti fas ligand antibodies
06/18/2009CA2708260A1 Improved immunizing composition
06/18/2009CA2707986A1 Compositions for pulmonary delivery
06/18/2009CA2707859A1 Antigen binding proteins
06/18/2009CA2705716A1 Novel rubella e1 envelope protein variants and their use in the detection of anti-rubella antibodies
06/17/2009EP2070949A2 Gene differentially expressed in breast and bladder cancer and encoded polypeptides
06/17/2009EP2070948A1 Humanized Anti-CD4 antibody with immunosuppressive properties
06/17/2009EP2070947A1 Therapeutic and diagnostic anti-Hsp70 antibodies
06/17/2009EP2070945A1 Genes of an otitis media isolate of nontypeable haemophilus influenzae
06/17/2009EP2070944A1 Specific binding agents of human angiopoietin-2
06/17/2009EP2070548A1 Diagnosis and treatment of cancer using anti-ereg antibody
06/17/2009EP2070546A1 Preventives/remedies for cancer
06/17/2009EP2069798A2 Elisa for vegf
06/17/2009EP2069784A1 Il-33 in inflammatory disease
06/17/2009EP2069558A2 Design and construction of diverse synthetic peptide and polypeptide libraries
06/17/2009EP2069499A2 Endophyte enhanced seedlings with increased pest tolerance
06/17/2009EP2069498A1 Inhibitory polynucleotide compositions and methods for treating cancer
06/17/2009EP2069478A2 Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
06/17/2009EP2069404A1 Humanized anti-cd100 antibodies
06/17/2009EP2069403A2 High affinity human antibodies to human il-4 receptor
06/17/2009EP2069402A2 Serum albumin binding proteins with long half-lives
06/17/2009EP2069401A1 Multispecific epitope binding proteins and uses thereof
06/17/2009EP2069400A1 Methods of treating rsv infections and related conditions
06/17/2009EP2069399A2 Interferons of rhesus and cynomolgus origin and uses thereof
06/17/2009EP2069396A2 Modified human plasma polypeptide or fc scaffolds and their uses
06/17/2009EP2069395A1 Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma
06/17/2009EP2069384A2 Biomarker fragments for the detection of human bnp
06/17/2009EP2069379A2 Methods for improving antibody production
06/17/2009EP2068929A2 Method for detecting and treating skin disorders
06/17/2009EP2068927A1 Methods of reducing eosinophil levels
06/17/2009EP2068926A2 Il-9 in fibrotic and inflammatory disease
06/17/2009EP2068924A2 Interferon alpha-induced pharmacodynamic markers
06/17/2009EP2068922A2 Anti-il-13r alpha 1 antibodies and their uses thereof
06/17/2009EP2068921A2 High affinity antibody antagonists of interleukin-13 receptor alpha 1
06/17/2009EP2068914A2 Antibody library display by yeast cell plasma membrane
06/17/2009EP2068887A2 Sp35 antibodies and uses thereof
06/17/2009EP1602669B1 Antibody against a tumor-specific antigen as target
06/17/2009EP1409544B1 Human dr4 antibodies and uses thereof
06/17/2009EP1390408A4 A molecular marker
06/17/2009EP1135511B1 Phosphonate metabolizing plants
06/17/2009EP1015496B1 Divalent anti-t cells immunotoxins and use thereof
06/17/2009CN101460522A Glycosylated antibodies
06/17/2009CN101460521A Hepatocyte growth factor (HGF) binding proteins
06/17/2009CN101460520A Hepatocyte growth factor (HGF) binding proteins
06/17/2009CN101460519A Human binding molecules having killing activity against staphylococci and uses thereof
06/17/2009CN101460518A Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
06/17/2009CN101456912A Anti P selectin single-chain antibody and use thereof
06/17/2009CN100500210C Use of il-18 inhibitors in hypersensitivity disorders
06/16/2009US7547817 For producing high affinity, fully human antibodies of a desired isotype in response to immunization with any virtually any desired antigen